Considerations for personalized neoantigen vaccination in Malignant glioma

Gavin P. Dunn, Ngima Sherpa, Jimmy Manyanga, Tanner M. Johanns

Research output: Contribution to journalReview articlepeer-review

Abstract

Malignant gliomas are the most common primary brain cancer diagnosed and still carry a poor prognosis despite aggressive multimodal management. Despite the continued advances in immunotherapy for other cancer types, however, there remain no FDA approved immunotherapies for cancers such as glioblastoma. OF the many approaches being explored, cancer vaccine programs are undergoing a renaissance due to the technological advances and personalized nature of their contemporary design. Neoantigen vaccines are a form of immunotherapy involving the use of DNA, mRNA, and proteins derived from non-synonymous mutations identified in patient tumor tissue samples to stimulate tumor-specific T-cell reactivity leading to enhance tumor targeting. In the last several years, the study of neoantigens as a therapeutic target has increased, with the routine workflow implementation of comprehensive next generation sequencing and in silico peptide binding prediction algorithms. Several neoantigen vaccine platforms are being evaluated in clinical trials for malignancies including melanoma, pancreatic cancer, breast cancer, lung cancer, and glioblastoma, among others. In this review, we will review the concept of neoantigen discovery using cancer immunogenomics approaches in glioblastoma and explore the disease-specific issues being addressed in the design of effective personalized cancer vaccine strategies.

Original languageEnglish
Article number114312
JournalAdvanced Drug Delivery Reviews
Volume186
DOIs
StatePublished - Jul 2022

Fingerprint

Dive into the research topics of 'Considerations for personalized neoantigen vaccination in Malignant glioma'. Together they form a unique fingerprint.

Cite this